Evidence map›Paper›PMID 40127182›Full record

ArticleBriefings in bioinformatics2025

PCLSurv: a prototypical contrastive learning-based multi-omics data integration model for cancer survival prediction.

Zhimin Li, Wenlan Chen, Hai Zhong, Cheng Liang

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhimin LiSchool of Information Science and Engineering, Shandong Normal University, Jinan 250358, China.
Wenlan ChenSchool of Computer Science and Engineering, Central South University, Changsha 410083, China.
Hai ZhongDepartment of Radiology, the Second Hospital of Shandong University, Jinan 250033, China.
Cheng LiangSchool of Information Science and Engineering, Shandong Normal University, Jinan 250358, China.ORCID 0000-0003-3832-0969

Funding

Jinan Clinical Medical Science and Technology Innovation Plan Project 202430031National Natural Science Foundation of China 62372279Natural Science Foundation of Shandong Province ZR2023MF119
6 · The paper itself

Abstract

Accurate cancer survival prediction remains a critical challenge in clinical oncology, largely due to the complex and multi-omics nature of cancer data. Existing methods often struggle to capture the comprehensive range of informative features required for precise predictions. Here, we introduce PCLSurv, an innovative deep learning framework designed for cancer survival prediction using multi-omics data. PCLSurv integrates autoencoders to extract omics-specific features and employs sample-level contrastive learning to identify distinct yet complementary characteristics across data views. Then, features are fused via a bilinear fusion module to construct a unified representation. To further enhance the model's capacity to capture high-level semantic relationships, PCLSurv aligns similar samples with shared prototypes while separating unrelated ones via prototypical contrastive learning. As a result, PCLSurv effectively distinguishes patient groups with varying survival outcomes at different semantic similarity levels, providing a robust framework for stratifying patients based on clinical and molecular features. We conduct extensive experiments on 11 cancer datasets. The comparison results confirm the superior performance of PCLSurv over existing alternatives. The source code of PCLSurv is freely available at https://github.com/LiangSDNULab/PCLSurv.

Indexed as

Computational BiologyDeep LearningGenomicsNeoplasmsSoftwareHumansMultiomicsPrognosisSurvival Analysismulti-omics integrationprototypical contrastive learningsurvival prediction

Identifiers

PMID40127182
PMCPMC11932092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.